Terms: = Kidney tumors AND PR, PGR, progesterone receptor AND Clinical Outcome
6 results:
1. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract] [Full Text] [Related]
2. Combined assessment of low pgrMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma.
He Y; Zhang P; Zhang D; Xia Z; Wang X; Deng S; Li H; Zhu H; Xu N; Liang S
Oncol Rep; 2018 Sep; 40(3):1467-1476. PubMed ID: 30015972
[TBL] [Abstract] [Full Text] [Related]
3. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract] [Full Text] [Related]
4. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B
Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567
[TBL] [Abstract] [Full Text] [Related]
5. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
[TBL] [Abstract] [Full Text] [Related]
6. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract] [Full Text] [Related]
